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Abstract
Background: The mechanisms by which smoking cessation reduces cardiovascular disease risk are unclear. We evaluated
longitudinal changes in carotid intima-media thickness among current smokers enrolled in a prospective, randomized
smoking cessation clinical trial.
Methodology/Principal Findings: Subjects were enrolled in a randomized, double-blind, placebo-controlled trial of 5
smoking cessation pharmacotherapies and underwent carotid ultrasonography with carotid intima-media thickness
measurement. Subjects were classified as continuously abstinent (biochemically confirmed abstinence at 6 months, 1 year,
and 3 years post-quit attempt), intermittently abstinent (reported smoking at one of the three time points), or smoked
continuously (reported smoking at all three time points). The primary endpoint was the absolute change (mm) in carotid
intima-media thickness (DCIMTmax) before randomization and 3 years after the target quit date. Pearson correlations were
calculated and multivariable regression models (controlling for baseline CIMTmax and research site) were analyzed. Among
795 subjects (45.2610.6 years old, 58.5% female), 189 (23.8%) were continuously abstinent, 373 (46.9%) smoked
continuously, and 233 (29.3%) were abstinent intermittently. There was a greater increase in carotid intima-media thickness
among subjects who were continuously abstinent than among those who smoked continuously (p=0.020), but not
intermittently (p=0.310). Antihypertensive medication use (p=0.001) and research site (p,0.001) independently predicted
DCIMTmax – not smoking status. The greatest increase in carotid intima-media thickness among continuous abstainers was
related to increases in body-mass index (p=0.043).
Conclusions/Significance: Smoking status did not independently predict DCIMTmax; increasing body-mass index and
antihypertensive medication use were the most important independent predictors. The rapid reduction in cardiovascular
disease events observed with smoking cessation is unlikely to be mediated by changes in subclinical atherosclerosis burden.
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Introduction
It has been hypothesized that the strong relationship between
cigarette smoking and the development of cardiovascular disease
(CVD) is mediated by inflammatory pathways, lipid oxidation, and
vascular dysfunction [1,2]. Smoking cessation reduces cardiovas-
cular disease risk; however, the mechanisms and time-course of the
effects of cessation on CVD risk are unknown [3–5]. In some
studies cardiovascular disease risk begins to decrease within 3 years
of smoking cessation [3,4]. Carotid intima-media thickness
(CIMT) is a measure of subclinical arterial injury that predicts
future cardiovascular disease events. In cross-sectional analyses, we
and others previously demonstrated that smoking intensity (pack-
years) was associated with increased CIMT [6,7]. The purpose of
this paper was to describe longitudinal 3-year changes in CIMT
observed in a large, modern cohort of current smokers enrolled in
a prospective, randomized clinical trial of smoking cessation
pharmacotherapies and to determine if smoking cessation is
associated with a reduction in progression in CIMT.
Methods
The protocol for this trial and support CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1. Also included as supporting information is a manuscript by
Piper, et al.; see Piper S1.
Study Procedures
Ethics Statement. This study was approved by the
institutional review board of the University of Wisconsin School
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35332of Medicine and Public Health. It was conducted according to the
principles expressed in the Declaration of Helsinki. All participants
provided written informed consent.
Subjects were enrolled in a randomized, double-blinded,
placebo-controlled comparative effectiveness trial of smoking
cessation pharmacotherapies that also intended to study the
natural history of smoking and cessation on subclinical athero-
sclerosis [6,8]. Each participant’s consent for the randomized
clinical trial included permission to evaluate the physiologic effects
of active cigarette use and smoking cessation on atherosclerosis by
ultrasonographic evaluation of CIMT at baseline and after 3 years.
At the baseline and year 3 visits, anthropometric data, fasting
laboratory tests, validated questionnaires, and interviews were
completed. Participants were randomized to one of six treatment
conditions: nicotine lozenge, nicotine patch, sustained-release
bupropion, nicotine patch plus nicotine lozenge, sustained-release
bupropion plus nicotine lozenge, or placebo. Inclusion and
exclusion criteria were based on participation in the clinical trial.
Inclusion criteria were age $18 years, current smoking of $10
cigarettes?day for the previous 6 months, an expired carbon
monoxide level of .9 ppm, and stated motivation to try to quit
smoking. Major exclusion criteria were uncontrolled hypertension
(blood pressure .160?100 mmHg) and myocardial infarction in
the previous 4 weeks. Additional study details, including the
flowchart of participants, have been reported previously [6,8].
Carotid Ultrasonography
Subjects underwent carotid ultrasonography with CIMT
measurement prior to randomization and 3 years after the target
quit date at two research sites in Milwaukee and Madison,
Wisconsin [6,8]. Maximum right- and/or left-sided far wall
common carotid artery CIMT measurements were averaged. The
far wall CIMT of the distal 1 cm of each common carotid artery
was measured in triplicate at the electrocardiographic R-wave
using a high-resolution linear array transducer (L10–5) and
cardiovascular ultrasound system (CV70; Siemens Medical
Solutions, Mountain View, WA) [6]. The CIMT imaging protocol
has been described previously [9]. Images were transferred via the
Internet to a secure Web server at the University of Wisconsin
Atherosclerosis Imaging Program, the core ultrasound laboratory.
All scanners were trained and certified by the core lab. A single
reader blindly measured all baseline and follow-up images using a
semi-automated border detection tool [8]. At the time of CIMT
image analysis, approximately 130 participants were excluded
because the year 3 CIMT scan images did not match the baseline
images closely enough for comparative analysis (Figure 1). This
was a predefined exclusion criterion. The primary endpoint was
the absolute change (mm) in CIMT (DCIMTmax) between baseline
and year 3. The coefficient of variation for repeatability of
CIMTmax measurements was 3.46%. Subjects were classified as
continuously abstinent (biochemically confirmed abstinence at 6
months, 1 year, and 3 years post-quit attempt), intermittently
abstinent (reported smoking at one of the three time points), or
smoked continuously (reported smoking at all three time points).
Statistical Analysis
Analyses were performed with SPSS software (SPSS, Inc.,
Chicago, IL). Our sample size estimate was based on the effect size
of abstinence from smoking (compared to continued smoking)
reported in statistical models from the Atherosclerosis Risk in
Communities Study that adjusted for CVD risk factors and
environmental tobacco smoke [7]. Our target sample size was 750
participants (300 abstainers and 450 smokers), based on a
conservative 5–10% attrition rate from baseline to Year 3. We
hypothesized that the DCIMTmax of continuing smokers would
progress at a rate of approximately 0.043 mm/3 years and former
smokers would progress at a rate of approximately 0.035 mm/3
years for an absolute difference of 0.007–0.008 mm/3 years, a
relative decrease (treatment effect) of 17%. We used a two-tailed
a=0.05 to determine that we had 81% power to detect a 20%
difference in progression between abstinent and smoking partic-
ipants.
CVD risk factors and CIMT were described by means 6
standard deviations, unless noted otherwise. Pearson correlations
were estimated between DCIMTmax and current age, separately
for the baseline values and the 3-year change values for the
following continuous variables: body mass index (BMI), waist
circumference, carbon monoxide levels, current pack-years
smoking, heart rate, systolic blood pressure, diastolic blood
pressure, total cholesterol, triglycerides, low-density lipoprotein
cholesterol (LDL), high-density lipoprotein (HDL) cholesterol,
fasting glucose, hemoglobin A1C, high sensitivity C-reactive
protein, average number of alcohol-containing beverages per
month, and mean CIMT. Pearson correlations also were
estimated between DCIMTmax and baseline Fa ¨gerstrom Test for
Nicotine Dependence score (total). A one-way ANOVA was
performed between DCIMTmax and smoking status groups and
smoking cessation treatment arms (placebo, bupropion, lozenge,
patch, bupropion + lozenge, patch + lozenge). T-tests were
performed to compare the change in DCIMTmax between genders,
races (white vs. non-white), research sites (Madison vs. Milwaukee,
WI), and subjects who did and did not use lipid-lowering
medications (yes/no) or anti-hypertensive medications (yes/no).
The best-fitting multivariable linear regression models were
developed using a backward model-building approach (Hosmer
& Lemeshow) for DCIMTmax. All variables with p,0.20 in
individual analyses were added to the model. Predictors were then
systematically removed until only statistically significant (p,0.05)
predictors remained, controlling for baseline CIMTmax and
research site.
Results
The 795 subjects (45.2610.6 years old, 58.5% female) who had
CIMT scans at baseline and year 3 are described in Table 1.
There were 189 (23.8%) subjects who were continuously abstinent,
373 (46.9%) smoked continuously, and 233 (29.3%) were abstinent
intermittently. Abstinence rates did not differ by gender
(p=0.410).
Age was significantly correlated with baseline cigarettes
smoked/day (r=0.17, p,0.001) but was not correlated with
DCIMTmax (r=0.04, p=0.321). DCIMTmax was correlated
weakly, but significantly, with 3-year changes in LDL cholesterol
(r=-0.10, p=0.007), total cholesterol (r=-0.09, p=0.020),
hemoglobin A1C (r=0.08, p=0.030), and use of antihypertensive
medications at either visit (r=0.11, p=0.002). DCIMTmax did not
differ between smoking cessation treatment arms (p=0.993), by
sex (p=0.146), race (p=0.338), or age (p=0.321). There was a
greater increase in CIMT among subjects at the Milwaukee site
(p,0.001) and among subjects who were continuously abstinent
compared to those who smoked continuously (p=0.020) but not
intermittently (p=0.310).
Some CIMT predictors were significantly different between the
Madison and Milwaukee research sites. Important demographic
differences between sites were gender (p=0.048), age (p=0.003),
race (p,0.001), marital status (p=0.029), education (p,0.001),
and Fa ¨gerstrom Test for Nicotine Dependence score (p=0.021).
Abstinence rate (p,0.001), antihypertensive medication use
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(p=0.048), HgbA1C (p,0.001), and LDL cholesterol (p=0.001)
differed between sites.
ANOVA tests with post-hoc analysis were performed to
compare 3-year changes in CIMT predictors to the three smoking
classifications. Continuously abstinent participants smoked fewer
cigarettes/day at baseline (p=0.023) and by year 3 had a greater
increase in HDL cholesterol (p=0.001), less increase in LDL
cholesterol (p=0.031), and greater increase in glucose (p=0.036)
than both those who smoked continuously and those who were
intermittently abstinent. Those who were intermittently abstinent
had greater increases in body-mass index by year 3 than those who
smoked continuously (p=0.030), but not those who were
continuously abstinent (p=0.292).
Using all biological, demographic, site, and cessation parame-
ters as candidate variables, and controlling for baseline CIMTmax
and site, the only independent associations of DCIMTmax in the
best-fitting linear regression model were anti-hypertensive medi-
cation use (standardized b=0.15, p=0.001) and site (b=0.31,
p,0.001). At the Milwaukee site, use of antihypertensive
Figure 1. CONSORT: Screening, Randomization, Baseline Imaging and Follow-up.
doi:10.1371/journal.pone.0035332.g001
Smoking, Cessation and Arterial Disease
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associated with DCIMTmax; at the Madison site, male sex
(p=0.015) was the only variable independently associated with
DCIMTmax. In the entire subject population, neither baseline
smoking burden, baseline smoking intensity, nor abstinence status
were independently associated with DCIMTmax. Change in BMI
(p=0.031), antihypertensive medication use (p=0.019), and
continuous abstinence (p=0.040) were weakly but independently
associated with being in the highest quartile of DCIMTmax. These
effect sizes were modest (R
2
adj=0.032).
Based upon these findings we conducted exploratory mediation
analysis using the conservative Baron and Kenny [10] approach
and the joint significance test to examine how the direct path from
smoking status to DCIMTmax was affected by the inclusion of the
change in BMI over 3 years. Linear regression analyses were
performed among continuously abstinent subjects whose DCIMT-
max was in the top or bottom quartile. There were significant
effects of smoking status on the change in BMI (b = 0.225, p
,0.001) and significant effects of the change in BMI on
DCIMTmax (b = 0.124, p = 0.015). Both of the indirect paths
were sufficient to conclude mediation using the joint significance
test [11]. Subsequently, we assessed the direct effect of smoking
status on DCIMTmax when change in BMI was added to the
model and the direct effect changed from b = 0.126 (p = 0.012)
to beta =0.102 (p = 0.048) suggestive of mediation.
Discussion
After smoking cessation, CVD risk decreases within 3 years
[3,4]. We hypothesized that CIMT progression would be reduced
after 3 years of smoking cessation, but it was not. Male sex,
increasing BMI, and antihypertensive medication use were the
most important independent predictors of DCIMTmax. We also
observed a powerful site effect that could not be explained by any
patient or technical factors evaluated. Smoking status did not
independently predict DCIMTmax; indeed, individuals who were
continuously abstinent had a nominally greater increase in CIMT.
In this same population we demonstrated previously that
endothelial function improved [12] and HDL cholesterol, total
HDL, and large HDL particles increased [13], within the first year
after smoking cessation, despite weight gain. Therefore, the early
decrease in CVD risk observed after smoking cessation may be due
to improved endothelial function, CVD risk factors, and perhaps
unmeasured factors related to hemostasis and thrombosis.
The longitudinal effects of smoking cessation on subclinical
arterial disease are less clear. Such effects may require more than 3
years to emerge or might have been masked by BMI increases
among abstainers. In this same cohort we previously described an
increase in waist circumference and lack of a significant reduction
in high-sensitivity C-reactive protein levels after 1 year of cessation
[12,14], both of which may influence short-term changes in
CIMT. A previous study suggested that C-reactive protein levels
require approximately 5 years to return to baseline after smoking
cessation, even after controlling for other cardiovascular disease
risk factors [15]. Both short- and long-term decreases in CVD risk
after smoking cessation are well-established [3–5], and the
beneficial effects of smoking cessation clearly outweigh any
adverse metabolic effects. Thus, the decrease in CVD morbidity
and mortality after cessation is likely due to multiple mechanistic
pathways with differing temporal responses to smoking cessation.
This study highlights the limitations of CIMT as a surrogate
marker for short-term CVD risk reduction after smoking cessation
due to the complex vascular pathophysiology associated with
cessation.
Limitations of this study include between-site differences and a
relatively small sample size of continuous abstainers. In addition,
the lack of longitudinal carotid plaque assessment limits further
evaluation of confounding factors associated with subclinical
atherosclerosis and smoking cessation. It also is possible that
changes in the internal carotid or bulb CIMT may have been
different than we observed in the common carotid artery. We did
not assess the incidence of CVD events during this short-term
follow-up. Our 3-year drop-out rate (38.2%) is consistent with
previous smoking cessation trials [12]. A larger prospective clinical
trial with longer follow-up and combined CIMT and plaque
assessment is needed to better understand the effects of smoking
cessation on subclinical arterial disease.
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